Mannkind (MNKD) Shares Outstanding (Weighted Average) (2010 - 2026)
Mannkind (MNKD) reported Shares Outstanding (Weighted Average) of $308.3 million for Q1 2026, up 1.58% year-over-year from $303.5 million in Q1 2025, and up 0.86% quarter-over-quarter from $305.6 million in Q4 2025.
Mannkind (MNKD) Shares Outstanding (Weighted Average) (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $308.3 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $308.3 million, up 1.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $308.3 million (up 1.58% YoY), and the FY2025 annual result was $305.6 million, up 11.38% from the prior year.
- Shares Outstanding (Weighted Average) grew to $308.3 million in Q1 2026 per MNKD's latest filing, from $305.6 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $308.3 million in Q1 2026 and troughed at $251.9 million in Q1 2022.
- A 5-year average of $276.6 million and a median of $270.4 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) rose 12.25% in 2025, then grew 1.58% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $257.1 million in 2022, then gained by 3.86% to $267.0 million in 2023, then gained by 2.77% to $274.4 million in 2024, then grew by 11.38% to $305.6 million in 2025, then gained by 0.86% to $308.3 million in 2026.
- Business Quant data shows MNKD's Shares Outstanding (Weighted Average) at $308.3 million in Q1 2026, $305.6 million in Q4 2025, and $306.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 928.40 Mn |
| 10 | Mannkind | 1.13 Bn | 995.19 Mn | 82.66 Mn | 308.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 308.27 Mn |
| Dec 31, 2025 | 305.64 Mn |
| Sep 30, 2025 | 306.81 Mn |
| Jun 30, 2025 | 304.95 Mn |
| Mar 31, 2025 | 303.48 Mn |
| Dec 31, 2024 | 274.42 Mn |
| Sep 30, 2024 | 275.00 Mn |
| Jun 30, 2024 | 273.06 Mn |
| Mar 31, 2024 | 270.36 Mn |
| Dec 31, 2023 | 267.01 Mn |
| Sep 30, 2023 | 266.13 Mn |
| Jun 30, 2023 | 265.63 Mn |
| Mar 31, 2023 | 263.97 Mn |
| Dec 31, 2022 | 257.09 Mn |
| Sep 30, 2022 | 254.97 Mn |
| Jun 30, 2022 | 253.64 Mn |
| Mar 31, 2022 | 251.89 Mn |
| Dec 31, 2021 | 249.24 Mn |
| Sep 30, 2021 | 248.62 Mn |
| Jun 30, 2021 | 247.97 Mn |